Ironwood Pharmaceuticals Will Present Late-breaking Data During The 2024 Digestive Disease Week Meeting From Its Phase 3 STARS Trial Of Apraglutide For Short Bowel Syndrome With Intestinal Failure
$IRWD
Biotechnology: Pharmaceutical Preparations
Health Care
- New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24
- Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients –
- Data from largest GLP-2 Phase III study to date adds to body of evidence on safety and efficacy of once-weekly apraglutide in adults with SBS-IF –
- New details on safety and tolerability to be presented; showing apraglutide to be well tolerated with a safety profile consistent with previously reported apraglutide studies in this patient population